Pharmacological inhibition of phosphatiylinositide-3-kinase (PI3K)-mediated signaling holds great promise for treating chronic lymphocytic leukemia (CLL). Therefore we assessed three structurally related PI3K inhibitors targeting the PI3K-d isoform for their ability to inhibit the survival of freshly isolated CLL cells. The purely PI3K-d-selective inhibitor idelalisib was compared to copanlisib and duvelisib (IPI-145), with isoform target profiles that additionally include PI3K-a or PI3K-c, respectively. The concentrations leading to half-maximal reduction of the survival of CLL cells were more than ten-fold lower for copanlisib than for idelalisib and duvelisib. At concentrations reflecting the biological availability of the different inhibitors, high levels of apoptotic response among CLL samples were attained more consistently with copanlisib than with idelalisib. Copanlisib selectively reduced the survival of CLL cells compared to T cells and to B cells from healthy donors. In addition copanlisib and duvelisib impaired the migration of CLL cells towards CXCL12 to a greater extent than equimolar idelalisib. Similarly copanlisib and duvelisib reduced the survival of CLL cells in co-cultures with the bone marrow stroma cell line HS-5 more strongly than idelalisib. Survival inhibition by copanlisib and idelalisib was enhanced by the monoclonal CD20 antibodies rituximab and obinutuzumab (GA101), while antibody-dependent cellular cytotoxicity mediated by alemtuzumab and peripheral blood mononuclear cells was not substantially impaired by both PI3K inhibitors for the CLL-derived JVM-3 cell line as target cells. Taken together, targeting the a-and d-p110 isoforms with copanlisib may be a useful strategy for the treatment of CLL and warrants further clinical investigation.Chronic lymphocytic leukemia (CLL) is a common B cell malignancy that usually occurs at advanced age and follows a highly variable course. 1 Although management of the disease has been steadily improved, with chemo-immunotherapy by fludarabine, cyclophosphamide and rituximab (FCR) as the current treatment standard for patients without co-morbidity, 2 there is a need for more efficient and less toxic therapies, since CLL can only be cured by allogeneic stem cell transplantation. Therefore, novel targeted agents are being developed, some of which show great promise and might replace chemotherapy regimens in the near future. 3
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.